These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2399833)

  • 1. The lymphatic route. VII. Distribution of recombinant human interleukin-2 in rabbit plasma and lymph.
    Bocci V; Pessina GP; Nicoletti C; Paulesu L
    J Biol Regul Homeost Agents; 1990; 4(1):25-9. PubMed ID: 2399833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lymphatic route. VI. Distribution of recombinant interferon-alpha 2 in rabbit and pig plasma and lymph.
    Bocci V; Pessina GP; Paulesu L; Nicoletti C
    J Biol Response Mod; 1988 Aug; 7(4):390-400. PubMed ID: 3171601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
    Chen SA; Sawchuk RJ; Brundage RC; Horvath C; Mendenhall HV; Gunther RA; Braeckman RA
    J Pharmacol Exp Ther; 2000 Apr; 293(1):248-59. PubMed ID: 10734176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentration profiles of human recombinant interleukin-2 (HrIL-2) in the rat following administration by various systemic routes.
    Colburn WA; Hakimi J; Bekersky I
    Drug Metab Dispos; 1987; 15(3):429-31. PubMed ID: 2886323
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer.
    Gustavson LE; Nadeau RW; Oldfield NF
    J Biol Response Mod; 1989 Aug; 8(4):440-9. PubMed ID: 2787839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of recombinant interleukin 2 in humans.
    Konrad MW; Hemstreet G; Hersh EM; Mansell PW; Mertelsmann R; Kolitz JE; Bradley EC
    Cancer Res; 1990 Apr; 50(7):2009-17. PubMed ID: 2317789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encapsulation of interleukin-2 in murine erythrocytes and subsequent deposition in mice receiving a subcutaneous injection.
    DeLoach JR; Andrews K; Sheffield CL
    Biotechnol Appl Biochem; 1988 Apr; 10(2):183-90. PubMed ID: 3260104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lymphatic route. V. Distribution of human natural interferon-beta in rabbit plasma and lymph.
    Bocci V; Pessina GP; Paulesu L; Muscettola M; Valeri A
    J Interferon Res; 1988 Oct; 8(5):633-40. PubMed ID: 3235848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration.
    Anderson PM; Katsanis E; Sencer SF; Hasz D; Ochoa AC; Bostrom B
    J Immunother (1991); 1992 Jul; 12(1):19-31. PubMed ID: 1637781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
    Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
    Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
    Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
    Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tissue distribution of human recombinant interleukin-2 in mice.
    Tang ZM; Liu XW; Xu LP; Shan CW; Song QS
    Zhongguo Yao Li Xue Bao; 1994 Jan; 15(1):51-6. PubMed ID: 8010086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability in rats of human recombinant tissue plasminogen activator after subcutaneous and intramuscular injection.
    Garcia Frade LJ; Poole S; Hanley S; Creighton LJ; Curtis AD; Gaffney PJ
    Thromb Haemost; 1986 Dec; 56(3):299-301. PubMed ID: 3105106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of recombinant human follicle stimulating hormone after intravenous, intramuscular, and subcutaneous administration in monkeys, and comparison with intravenous administration of urinary follicle stimulating hormone.
    Porchet HC; Le Cotonnec JY; Canali S; Zanolo G
    Drug Metab Dispos; 1993; 21(1):144-50. PubMed ID: 8095209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic integration of danofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits.
    Fernández-Varón E; Marin P; Escudero E; Vancraeynest D; Cárceles CM
    J Vet Pharmacol Ther; 2007 Feb; 30(1):18-24. PubMed ID: 17217396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep.
    McLennan DN; Porter CJ; Edwards GA; Martin SW; Heatherington AC; Charman SA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):345-51. PubMed ID: 15579493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
    Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
    Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic alteration in rats of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2.
    Sato J; Hamaguchi N; Doken K; Iwasa S; Ogawa Y; Toguchi H
    Biol Pharm Bull; 1994 Apr; 17(4):535-8. PubMed ID: 8069264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.